Keytruda Denied by Insurance? How to Appeal an Immunotherapy Denial

Keytruda (pembrolizumab), manufactured by Merck, is one of the most important cancer drugs ever developed — holding more FDA-approved oncology indications than any other drug in history — and one of the most frequently denied by insurance companies. With a list price exceeding $180,000 per year, insurers scrutinize Keytruda claims heavily. A denial is not the end. Here is how to fight back.

Why Insurers Deny Keytruda Claims

Keytruda denials follow predictable patterns that can each be challenged with specific legal and clinical arguments:

• "Not FDA-approved for your cancer type" — Keytruda has over 30 FDA-approved indications across more than 20 cancer types, plus tissue-agnostic approvals for MSI-H/dMMR and TMB-H tumors. Insurers sometimes apply narrow interpretation of indications; verify your specific cancer type and biomarker profile against the full FDA label
• "Off-label use" — When prescribed for an indication not in the FDA approval, Keytruda may be denied as off-label even when supported by NCCN Category 1 or 2A evidence; under ACA Section 2709 and Section 2719A, non-grandfathered plans must cover NCCN-included regimens
• "PDL1 expression doesn't meet threshold" — Some Keytruda indications require specific PDL1 expression levels (PDL1 ≥1%, ≥50%); if your result is near the threshold, the specific antibody used for testing (22C3, 28-8, SP142) matters
• "Biomarker testing not completed" — Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization for Keytruda almost always requires companion diagnostic testing results (PDL1, MSI/MMR, TMB) to be in the PA request
• "Step therapy required — try chemotherapy first" — For many indications, Keytruda is FDA-approved as first-line therapy; requiring chemotherapy first contradicts FDA approval and NCCN Category 1 evidence
• "Prior authorization errors" — Keytruda requires PA at virtually every plan; incomplete submission is common and correctable on appeal

Under ACA §2719 and ERISA §1133, you have the right to a written denial explanation, internal appeal, and independent External Independent Review: Complete Guide" class="auto-link">external review.

How to Appeal a Keytruda Denial

Step 1: Confirm Biomarker Testing Is Complete and Documented

Ensure your medical record contains complete biomarker testing results: PDL1 expression testing with the specific antibody used (22C3 is the FDA-approved companion diagnostic for most Keytruda indications), MSI/MMR testing results (IHC or PCR), TMB results if applicable, and any other relevant biomarkers for your cancer type (EGFR, ALK, BRAF, RET, etc.). Missing biomarker documentation is the most common correctable reason for PA denials.

Step 2: Get Your Oncologist to Write a Comprehensive Letter of Medical Necessity

The letter should include your exact cancer type, stage, histology, and complete biomarker profile; why Keytruda specifically was selected over alternatives; the FDA approval or NCCN guideline category supporting the choice; results of any prior treatments that have failed; and why you cannot use alternative treatments. This letter is the centerpiece of your appeal and must address the specific denial reason cited in your denial letter.

Step 3: Cite the Specific FDA Approval and NCCN Guideline Category

Look up your exact FDA indication at FDA.gov or the Drugs@FDA database. Include the approval date, specific indication, and any biomarker requirements. If your use is off-label but NCCN-supported, cite the specific NCCN guideline recommendation level (Category 1, 2A, or 2B) and note that major compendia (NCCN, Micromedex) support the use. Medicare and most commercial plans accept NCCN Compendium for off-label oncology coverage decisions.

Step 4: For Step Therapy Denials — Cite FDA First-Line Approval Data

Keytruda is FDA-approved as first-line therapy for many indications. Requiring chemotherapy first contradicts the FDA label and NCCN Category 1 evidence. Cite pivotal trial data: for first-line NSCLC with PDL1 ≥50%, cite KEYNOTE-024 (80.2% vs. 72.4% OS at 3 years favoring pembrolizumab); for first-line non-squamous NSCLC, cite KEYNOTE-189 (48.8% vs. 36.4% OS at 2 years with pembrolizumab plus chemotherapy).

Step 5: Request Expedited Review — Cancer Treatment Cannot Wait

Cancer treatment delays are medically urgent. Request expedited internal review under ACA §2719, which requires a decision within 72 hours. State specifically in writing why delay would jeopardize your health. Your oncologist should certify the urgent medical need.

Step 6: Request External Review After Internal Denial

Under ACA §2719, after an internal appeal denial you are entitled to external independent review. Contact your state insurance department or the DMHC (California members) for expedited external review. An independent reviewer applying current oncology standards — not the insurer's proprietary criteria — will evaluate your case.

What to Include in Your Appeal

• Insurance denial letter with the specific denial reason and policy provision identified
• Your member ID and claim number
• Complete biomarker testing results with specific antibodies and laboratory methods documented
• Oncologist's comprehensive letter of medical necessity addressing each denial criterion
• FDA drug label for Keytruda showing the specific approved indication for your cancer type and biomarker profile
• NCCN Clinical Practice Guidelines in Oncology for your cancer type showing the recommendation category
• Pivotal clinical trial data supporting first-line use if step therapy is cited

Fight Back With ClaimBack

Keytruda denials are among the most serious and most successfully challenged insurance decisions — particularly when the specific FDA approval or NCCN Category 1 evidence is clearly cited. A well-built appeal citing your oncologist's clinical judgment alongside regulatory standards significantly increases your odds of approval. ClaimBack generates a professional appeal letter in 3 minutes. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal